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2 
Abstract. 22 
 23 
The basal ganglia are implicated in a wide range of motor, cognitive and behavioural 24 
activities required for normal function. This region is predominantly affected in Huntington’s 25 
disease (HD), meaning that functional ability progressively worsens. However, functional 26 
outcome measures for HD, particularly those for the upper limb, are limited meaning there is 27 
an imperative for well-defined, quantitative measures.  28 
Here we describe the development and evaluation of the Moneybox test (MBT). This novel, 29 
functional upper limb assessment was developed in accordance with translational 30 
neuroscience and physiological principles for people with a broad disease manifestation, such 31 
as HD.   32 
Participants with HD (n=64) and healthy controls (n=21) performed the MBT, which required 33 
subjects to transfer tokens into a container in order of size (Baseline Transfer), value 34 
(Complex Transfer) with and without reciting the alphabet (Dual Transfer). Disease specific 35 
measures of motor, cognition, behaviour and function were collected. HD patients were 36 
grouped into disease stage, from which, discriminative and convergent validity was assessed 37 
using Analysis of Variance and Pearson’s correlation respectively.  38 
Manifest HD participants were slower than pre-manifest and control participants, and 39 
achieved significantly lower MBT total scores. Performance in the Complex Transfer and 40 
Dual Transfer tasks were significantly different between pre-manifest and stage 1 HD. All 41 
MBT performance variables significantly correlated with routinely used measures of motor, 42 
cognition, behaviour and function.  43 
The MBT provides a valid, sensitive and affordable functional outcome measure. Unlike 44 
current assessments, MBT performance significantly distinguished the subtle differences 45 
between the earliest disease stages of HD, which are the populations typically targeted in 46 
clinical trials.   47 
3 
1. Introduction. 48 
 49 
The basal ganglia is a highly organised group of interconnected, functionally subdivided, 50 
subcortical nuclei. Damage to the cortico-basal ganglia-thalamo circuitry plays an important 51 
role in multiple neurological conditions [1], such as Parkinson’s and Huntington’s disease 52 
(HD), with symptoms progressively effecting standards of living.  Neurodegenerative 53 
diseases are a leading cause of death globally [2] with limited potential for therapeutics to 54 
slow progression or prevent onset. In light of impending clinical trials of disease modifying 55 
interventions, well-defined clinical endpoints and relevant objective progression criteria will 56 
be essential to progress potential therapies to regulatory approval with relative efficiency. A 57 
major challenge to date is the reliance on patient reported outcomes for the assessment of 58 
function. Functional assessments are crucial to gain an understanding about how standards of 59 
living change a disease progresses, and also following an intervention. 60 
 61 
Selecting relevant outcome measures that best match the trial hypothesis is fundamental. To 62 
this end, there is an urgent need to develop novel assessments with high ecological validity 63 
and that also appropriately reflect the underlying neuropathology and the subsequent 64 
structure-function relationships [3,4]. Furthermore, to reduce the burden on patients and to 65 
reliably assess the effectiveness of developing therapies, it is important that assessments used 66 
in clinical trials are reliable, valid, as short as can be reasonably managed (in order to limit 67 
the burden on patients), and reflect clinically meaningful changes [5].   68 
 69 
HD is an autosomal dominant, inherited neurodegenerative disorder with a prevalence of 6-70 
13/100,000 in the general population. People with manifest HD suffer from complex disease 71 
symptoms, including progressive motor, cognitive and behavioral impairments, leading to 72 
gradual loss of functional independence and progressive escalation of healthcare costs over a 73 
15-30 year period [6]. Neurodegeneration in HD is widespread, but primarily involves 74 
degeneration of the cortico-basal ganglia-thalamo circuitry  [7–9], from which the striatum 75 
takes the brunt of the pathological burden. This degeneration is evident over a decade before 76 
symptom onset (termed pre-manifest) [10], and recognized as manifest when motor 77 
symptoms begin, as rated on the Unified Huntington’s disease rating scale (UHDRS) total 78 
motor score (UHDRS-TMS). The UHDRS-TMS is one of six standardised UHDRS 79 
assessments that are used to determine the range of clinical features associated with HD, 80 
which include a motor, cognitive, functional capacity, behavioural, functional assessment and 81 
an independence scale [11]. Although the current gold standard, many of the UHDRS scales 82 
are limited by their ordinal ratings. Furthermore, it is difficult to clearly relate scores that 83 
focus on disease impairment to how they affect activities of daily living. A relatively recent 84 
systematic review of outcome measures used in HD pharmacological trials highlighted 85 
reliance on clinical reported outcomes in the assessment of function in HD [12]. Many of 86 
these assessments require a clinician assessment of a patient’s ability to perform within 87 
relatively disparate domains, such as making a meal and dressing.  88 
 89 
We suggest that performance based assessments that relate to daily function and importantly 90 
include a focus on fine motor skills are critical to the sensitive and reliable assessment of 91 
function. However, whilst there is increasing recognition of the importance of upper limb and 92 
fine motor assessment in HD [13–18] , there remains relatively limited clinical literature on 93 
the topic. The Perdue Peg test [19] is a well-established upper limb functional test that has 94 
been used in a variety of settings and conditions but to our knowledge in two HD studies. The 95 
first where people with HD (n=6) were found to perform slower than healthy controls (n=12) 96 
[15] and the second, a far larger scale study in which peg insertion was found to discriminate 97 
4 
between manifest HD (n=140) and controls (n=57) or pre-manifest HD (n=34) but not pre-98 
manifest HD and controls [16].  . The 10 euro neuro test is a simple timed coin alignment test 99 
that was developed with the express view of assessing finger dexterity in HD [17]. It was 100 
found to be reliable and to discriminate between late stage HD (n=10) and healthy controls 101 
(n=14). There was some correlation with CAG repeat score however two of the 10 HD 102 
patients were not able to complete the tasks suggesting it could be subjective to floor effects. 103 
More recently, the nut and bolt test applied in pre-manifest HD (n=24) and manifest HD 104 
(n=27) and controls (n=32) was shown to be a useful measure of fine-motor coordination in 105 
HD [18]. Impairments in performance were seen at all stages of HD and in pre-manifest HD 106 
(non-dominant hand only) that were correlated with disease burden scores.  107 
 108 
Many activities of daily living require performing and synchronising multiple tasks (i.e., 109 
‘dual-’ or ‘multi-tasking’), which can be challenging as it requires dividing attention between 110 
each task that is performed. This can lead to performance deterioration in one or both tasks, 111 
which is exacerbated in people with a neurological disorder such as HD [20–22]. The type of 112 
tasks combined as well as the task complexity can also have an impact on performance. One 113 
study revealed that  people with HD had greater difficulty performing a motor-cognitive dual 114 
task than motor-motor [20], suggesting the former may be more sensitive to the cortico-basal 115 
ganglia circuitry disrupted in HD. 116 
   117 
The Moneybox test (MBT) was developed to to specifically target functions that involve the 118 
cortico-basal ganglia circuitry to quantitatively reflect the neurodegeneration in HD. The 119 
MBT incorporates three motor-cognitive items that increase in task difficulty, plus two 120 
baseline items which are performed as single tasks.  121 
 122 
Here we report the development and validation of the Moneybox test (MBT; Figure 1). The 123 
aim of this study was to validate the MBT in people with all stages of HD and in a group of 124 
age matched, healthy controls. We hypothesised that people with advanced HD would 125 
perform more slowly and less accurately than those in the earlier disease stages and that all 126 
people with HD would perform more slowly and less accurately with increased item 127 
complexity.    128 
 129 
<INSERT FIGURE 1> 130 
 131 
2. Materials and Methods. 132 
 133 
2.1 Participants. 134 
 135 
Eighty-five participants were recruited from the Cardiff HD research and management clinic 136 
between February 2016 and January 2017, from which twenty-one were gene-negative 137 
healthy controls (9 male) and sixty-two people were gene positive with HD (8 pre-manifest 138 
and 56 manifest; 38 male). The manifest group was further subdivided based on their 139 
UHDRS-Total functional capacity score (UHDRS-TFC) to form 4 groups (stage 1, TFC =11-140 
13 and TMS > 5; stage 2, TFC=7-10; stage 3, TFC=3-6; stage 4,5 =0-2). Participants in 141 
stages 4 and 5 were combined, forming the most advanced group. This was due to the lack of 142 
participants that were recruited in these stages. Ethical approval was obtained from South 143 
East Wales Research Ethics Committee (REC reference: 14/WA/1195). Inclusion criteria for 144 
the HD groups were (1) genetically confirmed diagnosis of HD; (2) over 18 years of age; (3) 145 
recruited onto Enroll-HD, which is a global observational study that provides researchers 146 
with access to non-identifiable clinical information (https://www.enroll-hd.org/). Exclusion 147 
5 
criteria included an inability to provide informed consent and any comorbid condition that 148 
had the potential to confound the results of the study.  149 
 150 
2.2 Assessments.  151 
 152 
Specific criteria were established to guide the overall MBT development process (see Table 153 
1). 154 
 155 
Table 1: Criteria used to develop the MBT  156 
Criteria MBT 
Restricted to upper limb function 
The MBT is performed seated and requires bilateral 
function to grasp, transfer and accurately release tokens 
into a container.  
Ecologically valid  
The MBT is a dual task assessment that consists of five 
items, from which three are transfer tasks with incremental 
difficulty; Baseline Transfer, Complex Transfer and Dual 
Transfer tasks. The remaining two items are baseline tasks 
to ensure the subject can count backwards from values 
presented and recite the alphabet in preparation for the 
Complex Transfer and Dual tasks respectively. The MBT 
was designed so it was sensitive for individuals with 
different levels of functional ability, such as people with 
HD. Reciting the alphabet was used for the Dual Transfer 
task to increase task complexity. This specific task was 
selected as it is less likely to be confounded by education 
or job type compared to other commonly used secondary 
tasks, such as addition, subtraction or verbal fluency tasks. 
The assessment is applicable to people 
with all stages of HD  
The MBT consists of a hierarchy of items with increasing 
levels of difficulty. Participants had to meet set criteria 
before proceeding to the more complex MBT items to 
minimise the chances of floor and ceiling effects. The 
pass/fail criteria is presented in the Supplementary 
material. 
The assessment is sensitive to  functions 
that involve the degenerating 
neuroanatomy in HD 
MBT items were developed to target behaviours that 
involve the cortico-basal ganglia-thalamo circuitry. This 
included: 
 
Dexterity: The lateral striatum is required for fine motor 
tasks [23]. To account for this, participants were required 
to pick up different sized tokens and accurately release 
these into a defined target on a container. 
 
Repeated motor transitions: Rhythmic, repeated motor 
transitions leads to a change in neuronal firing patterns in 
the dorsolateral striatum [24], and may relate to new skill 
learning [25]. The MBT was designed to take advantage of 
these functions, as the participant is required to repeatedly 
transfer eight tokens as quickly as possible into a container. 
 
Oculomotor function [26]: It was hypothesized that optimal 
MBT performance required occulo-motor function to 
rapidly saccade the eyes to the next token target. 
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 157 
The MBT procedure and the rating method is presented in Figure 2. The test items were 158 
carried out in the same order for each participant to ensure they could perform the baseline 159 
and the simpler tasks before proceeding to the more complex items. In addition, to minimise 160 
the floor and ceiling effects, participants had to meet set criteria before proceeding to the 161 
more complex MBT items (described in Supplementary material).         162 
 163 
<INSERT FIGURE 2 HERE> 164 
 165 
Additional information accessed through Enroll-HD included demographic information (age, 166 
gender and education level), the assessments from the UHDRS-TMS, TFC, functional score, 167 
independence score, and cognitive tests (Verbal fluency, Stroop task (word and colour 168 
naming) and the Symbol digit modalities test) [11]. The CAG disease burden score was 169 
calculated ((CAGn – 35.5)*Age) to estimate how close pre-manifest participants were to 170 
developing manifest symptoms  [32]. The apathy and executive function summaries from the 171 
Attention [27]: The increasing levels of difficulty in the 
MBT intended to demand increasing levels of attention. 
Throughout the MBT, participants are required to transfer 
tokens between hands and in a given order. In the Dual 
Transfer task, attentional capacity is challenged again as 
participants are required to transfer tokens in a set order 
whilst simultaneously reciting the alphabet. 
 
Alphabet recitation: Previous studies have shown that less 
cognitively demanding tasks can be more sensitive in 
people with HD than those with high cognitive demands 
[28,29]. In addition, pre-clinical research suggests that the 
dorsolateral striatum is involved in performing fixed, 
automatic behaviours [30]. Reciting the alphabet is a fairly 
simplistic task that is regularly recited from a young age. 
For many, by early adulthood, this recitation would pose 
little attentional demand as the memory is retrieved and 
automatically recited [24,25].  It was hypothesized that 
reciting the alphabet would load extra stress on the fronto-
striatal circuitry making the Dual Transfer task more 
challenging for people with striatal dysfunction. 
Minimal burden for the administrator  
and the participant 
The MBT is uncomplicated to set up and takes between 5-
10 minutes for the participant to perform. Due to the 
criteria developed for each MBT item, the length of the 
MBT assessment is dependent on the participant’s 
functional ability. In addition, as the MBT is used to 
measure bilateral function, unlike pegboard tests, it only 
need to be performed once, which reduces the time of the 
assessment. 
Compact 
As clinic space is often limited and equipment needs to be 
stored and transported to different clinic locations, the 
MBT was designed so it was compact, lightweight and so 
construction involved few and small test components.  
Quantitatively scored 
The MBT is quantitatively evaluated, using time as a 
primary measure, which can be combined with accuracy to 
calculate an MBT total score. This method was used to 
improve inter-rater reliability and to sensitively measure 
change over time [31].  
7 
Problem behaviour assessment, a questionnaire used to assess the behavioural symptoms in 172 
people with HD, were recorded [33]. The physical and mental summary scores from the Short 173 
form-12 were used to evaluate correlations with health related quality of life [34]. The Late-174 
life functional disability instrument, a questionnaire used to understand how much difficulty 175 
the participant has performing common daily activities, was used to provide a measure of 176 
construct validity [35].    177 
8 
2.3 Analyses.  178 
 179 
Demographic data and UHDRS scores were evaluated for all groups using the mean and the 180 
standard deviation. The mean performance scores were plotted with the standard error of the 181 
means (SEM) and the 95% confidence intervals.  182 
 183 
2.3.1 Discriminative validity 184 
 185 
Between group comparisons were made using analysis of variance (ANOVA). Independent 186 
subject factors included Group (control, pre-manifest or manifest participants) or TFC stage 187 
(TFC scores = 13 and UHDRS-TMS < 5, pre-manifest; 11–13, stage 1 (earliest symptomatic 188 
stage); 7–10, stage 2; 3–6, stage 3; 1–2, stage 4; and score of 0 is stage 5 (most advanced 189 
stage), or healthy controls). Dependent subject factors included MBT time (time), and MBT 190 
total score (total), value time (value time) and number of correct letters said per second 191 
(alphabet rate). A two way repeated measures ANOVA was used to evaluate any change in 192 
performance within group with increased item complexity in the MBT Complex Transfer and 193 
MBT Dual Transfer task compared to the MBT Baseline Transfer. The MBT transfer items 194 
(Baseline Transfer, Complex Transfer and Dual Transfer) and TFC group were used as 195 
factors. If the sphericity assumption was not met (p<0.05), this was corrected using the 196 
Greenhouse-Geisser test. A Bonferroni post hoc test was used for all ANOVA tests if results 197 
were deemed statistically significant (p<0.05).  198 
 199 
2.3.2 Convergent and construct validity 200 
 201 
Pearson’s correlation coefficients were used to reveal any associations between the MBT 202 
variables and the disease specific assessments of motor and cognitive ability, behaviour, 203 
function and health related quality of life.  204 
 205 
SPSS version 20 (PASW) (IBM Corporation, USA) was used for all analyses. 206 
  207 
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3. Results.  208 
 209 
Demographic and clinical information for all participants are presented in Table 2. There 210 
was no significant difference in age between controls and HD gene positive subjects, 211 
however the pre-manifest HD group were significantly younger than the manifest participants 212 
[F5,82=4.809, p<0.05]. Those in stage 2 manifest HD were significantly older than healthy 213 
controls [F5,79=3.285, p<0.01]. Level of education was not significantly different between 214 
controls, manifest and pre-manifest participants [F2,70=0.166, p=n.s.] or between any TFC 215 
disease stage [F5,67=0.296, p=n.s.].  216 
 217 
Table 2: Mean MBT participant demographic and clinical information revealed manifest 218 
subjects were significantly older than pre-manifest subjects, and stage 2 subjects were 219 
significantly older than healthy controls. There were no significant differences between any 220 
other group for any other variable. 221 
 222 
  Controls Pre-manifest Manifest Stage 1  Stage 2 Stage 3 Stages 4 and 5 
N (male: female) 21 (9:12) 8 (6:2) 56 (32:24) 23 (14:9) 17 (8:10) 11 (7:4) 3 (3:1) 
Age 45.52 (15.03) 37.75 (6.43) 51.21 (12.19) 48.43 (9.01) 
56.83 
(15.69) 50.55 (10.63) 43.75 (5.68) 
Total motor score   0.375 (0.52) 35.35 (21.07) 21.18 (12.1) 34.17 (12.24) 54.82 (19.23) 75 (20.88) 
Total functional 
capacity   12.625 (0.52) 8.87 (3.64) 12.09 (0.92) 8.94 (1.16) 4.64 (1.36) 0.33 (0.58) 
Functional scale   24.875 (0.35) 20.04 (5.97) 24.5 (0.74) 20.39 (1.46) 13.44 (4.5) 5 (7) 
Independence 
scale   99.375 (1.77) 81.3 (13.77) 91.90 (7.49) 79.44 (6.62) 67.22 (7.55) 50 (28.28) 
CAG disease 
burden score   260.71 (69.24) 400.29 (102.44) 373.39 (99.25) 
411.78 
(117.67) 424.73 (87.11) 429.38 (82.18) 
Education level † 3.58 (1.51) 3.75 (0.89) 3.53 (0.91) 3.71 (1.06) 3.39 (0.78) 3.45 (0.69) 3.33 (1.53) 
 223 
† Education level was missing in n=9 healthy controls 224 
 225 
Manifest participants were significantly slower in their performance of the MBT transfer 226 
tasks and achieved a significantly lower total scores than both pre-manifest and control 227 
participants. Performance in the MBT was also sensitive to disease stage. Participants in the 228 
more advanced disease stages were significantly slower and achieved lower MBT total scores 229 
than those in earlier disease stages [see Table 3 and Figure 3].  230 
 231 
 232 
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Table 3: Mean, standard deviation and 95% confidence intervals for time taken and mean 233 
MBT total scores achieved for each group (Control, Pre-manifest, Manifest; HD disease 234 
stage) during each of the MBT transfer items (MBT Baseline Transfer, Complex Transfer and 235 
Dual transfer). 236 
 237 
<INSERT FIGURE 3 HERE> 238 
 239 
 Group Time taken (seconds) 
95% confidence 
difference (upper-
lower bound) 
MBT total 
(no unit) 
95% confidence 
difference (upper-
lower bound) 
M
BT
 
Ba
se
lin
e 
Tr
a
n
sf
er
 
Control 14.34 ± 2.41 9.54 - 19.14 62 ± 2.73 56.55 - 67.45 
Pre-manifest 13.33 ± 4.46 4.45 - 22.21 62.69 ± 5.06 52.61 - 72.78 
Manifest 27.85 ± 2.15 23.301 - 32.15 34.97 ± 1.85 31.05 - 38.68 
ANOVA: F 
value and p 
value 
F(2,80)=9.551, p <0.001 F(2,80)=35.178, p<0.001 
Stage 1 20.59 ± 2.33 15.95 - 25.24 42.2 ± 2.65 36.92 - 47.47 
Stage 2 23.8 ± 2.65 18.51 - 29.08 35.18 ± 3.01 29.18 - 41.19 
Stage 3 46.62 ± 3.42 39.8 - 53.44 20.4 ± 3.89 12.65 - 28.14 
Stage 4,5 37.85 ± 6.3 25.29 - 50.41 27.77 ± 7.16 13.5 - 42.04 
ANOVA: F 
value and p 
value 
F(5,72)=14.25; p<0.001 F(5,72)=21.44; p<0.001 
M
BT
 
C
om
pl
ex
 
Tr
a
n
sf
er
 
Control 13.72 ± 2.39 8.95 - 18.49 59.32 ± 2.11 55.1 - 63.54 
Pre-manifest 14.78  ± 4.34 6.12 - 23.44 52.88 ± 3.84 45.22 - 60.55 
Manifest 33.59 ± 2.43 28.25-38.28 28.49 ± 1.73 25.06-32.23 
ANOVA: F 
value and p 
value 
F(2,75)=17.395, p <0.001 F(2,75)=61.856, p<0.001 
Stage 1 24.15 ± 2.39 19.38 - 28.91 36.51 ± 2.11 32.29 - 40.73 
Stage 2 30.4 ± 2.68 25.05 - 35.74 22.51 ± 2.37 22.51 - 31.97 
Stage 3 51.51 ± 3.67 44.19 - 58.83 17.05 ± 3.25 10.54 - 23.53 
Stage 4,5 54.64 ± 6.14 42.39 - 66.88 16.37 ± 5.43 5.53 - 27.21 
ANOVA: F 
value and p 
value 
F(5,67)=20.78; p<0.001 F(5,67)=38.45; p<0.001 
M
BT
 
D
ua
l T
ra
n
sf
er
 
Control 14.14 ± 2.13 9.89 - 18.39 55.67 ± 2.12 51.44 - 59.9 
Pre-manifest 14.89 ± 3.86 7.17 - 22.61 56.03 ± 3.84 48.35 - 63.71 
Manifest 33.44 ± 2.69 27.45-38.62 28.2 ± 1.64 25.05-31.87 
ANOVA: F 
value and p 
value 
F(2,71)=14.745, p <0.001 F(2,71)=55.864, p <0.001 
Stage 1 25.01 ± 2.13 20.76 - 29.26 34.75 ± 2.12 30.53 - 38.98 
Stage 2 28.97 ± 2.45 24.08 - 33.87 27.32 ± 6.66 22.45 - 32.19 
Stage 3 65.58 ± 3.86 57.86 - 73.3 13.58 ± 3.84 5.9 - 21.26 
Stage 4,5 32.44 ± 6.69 19.07 - 45.81 22.43 ± 6.66 9.12 - 35.73 
ANOVA: F 
value and p 
value 
F(5,63)=29.21; p<0.001 F(5,68)=31.38; p<0.001 
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Performance in the control and pre-manifest groups did not differ with increased task 240 
complexity. Participants across manifest disease stages were however significantly slower 241 
during performance of the more complex items (Complex Transfer and Dual Transfer task), 242 
compared to the Baseline Transfer [TFC stage x MBT item: Baseline Transfer vs Complex 243 
Transfer, F (5,72)= 4.65, p<0.001; Baseline Transfer vs Dual Transfer, F(5,68)= 7.68, p<0.001; 244 
Complex Transfer vs Dual Transfer, F(5,68)= 14.27, p<0.001]. In addition, more participants in 245 
the advanced disease stages failed to meet the pass/fail criteria required to proceed to the 246 
Complex Transfer and Dual Transfer items. This resulted in smaller group sizes as MBT 247 
items increased complexity and reduced the stage 4,5 group from 100% to 33% (from n=3 to 248 
n=1) in the Dual Transfer task.  In comparison, 95% and 100% of the control and pre-249 
manifest participants completed the whole MBT assessment (n=20 and n=8 respectively). 250 
 251 
Performance for all MBT variables significantly correlated with UHDRS measures except for 252 
the rate the alphabet was recited in the MBT Dual Transfer task vs the verbal fluency and the 253 
Stroop colour naming (see Table 4). Performance scores in the MBT items significantly 254 
correlated with CAG disease burden score, as well as the current performance based 255 
functional measures used for Enroll-HD (Timed up and go, and sit to stand), and the Late-256 
Life Functional Disability Instrument. MBT items also correlated with the SF-12 physical 257 
summary, but not the SF-12 mental summary or the executive function score from the 258 
Problem behaviour assessment.  The Dual Transfer total score also significantly correlated 259 
with the apathy calculation from the Problem behaviour assessment.260 
12 
Table 4: MBT convergent validity revealed that MBT performance (time and MBT total score) in the transfer tasks significantly correlated with 261 
all UHDRS motor, function and cognitive assessments. Performance in all transfer tasks significantly correlated with the SF-12 physical 262 
summary and functional assessments including the Timed Up and Go, Sit to Stand and the Late Life Functional Disability Instrument domains. 263 
There was also a significant correlation between the Dual Transfer and Problem Behaviour Assessment Apathy score. 264 
 265 
MBT = Moneybox test; UHDRS = Unified Huntington’s disease rating scale; TMS = Total motor score; TFC = Total functional capacity; FAS = 266 
functional assessment score; PBA = Performance behaviour assessment; SF-12 = Short-form 12; LL-FDI = Late life functional disability 267 
questionnaire. *p<0.05 (light grey); **p<0.01 (dark grey). 268 
  
UHDRS-
TMS 
UHDRS-
TFC 
TFC 
stage 
UHDRS-
FAS 
UHDRS 
Independence 
scale 
UHDRS 
symbol 
digit 
correct 
UHDRS 
verbal 
fluency 
correct 
UHDRS 
Stroop 
colour-
name 
correct 
UHDRS 
Stroop 
word-
reading 
correct 
CAG 
disease 
burden 
score 
Timed 
Up and 
Go 
Sit to 
Stand 
PBA 
apathy 
PBA 
executive 
function 
SF-12 
physical 
summary 
SF-12 
mental 
summary 
LL-FDI 
total 
LLFDI- upper 
extremity 
LLFDI- 
lower 
extremity 
MBT Time 
Baseline 
Transfer 
.775** -.627** .621** -.673** -.580** -.565** -.466** -.591** -.589** .379** .953** -.653** 0.1 -0.07 -.396* 0.112 -.423** -.460** -.437** 
MBT Time 
Complex 
Transfer 
.812** -.718** .719** -.702** -.651** -.619** -.480** -.608** -.633** .411** .915** -.700** 0.183 0.093 -.351* 0.039 -.439** -.448** -.471** 
MBT Time 
Dual 
Transfer 
.732** -.678** .632** -.678** -.635** -.559** -.391** -.563** -.587** 0.237 .940** -.702** 0.174 0.113 -.399* -0.284 -.517** -.537** -.537** 
MBT Total 
Baseline 
Transfer 
-.756** .633** -.618** .584** .574** .716** .468** .631** .609** -.489** -.667** .501** -0.183 -0.041 .355* 0.109 .507** .482** .468** 
MBT Total 
Complex 
Transfer 
-.791** .682** -.678** .616** .639** .719** .432** .599** .582** -.487** -.649** .560** -0.242 -0.147 .345* 0.098 .475** .413** .441** 
MBT Total 
Dual 
Transfer 
task 
-.777** .655** -.604** .586** .674** .741** .428** .647** .633** -.377** -.637** .570** -.294* -0.155 0.326 0.257 .488** .438** .461** 
Value 
Baseline .674** -.631** .639** -.701** -.666** -.546** -.432** -.581** -.609** .302* .704** -.561** .392** 0.156 -.447** 0.081 -.433** -.513** -.456** 
Alphabet 
Baseline -.439
**
 .475** -.367** .462** .421** .421** .348** .415** .400** -0.185 -0.197 .535** -0.089 -.254* .393* 0.266 .422** .453** .462** 
Alphabet 
Dual task -.405** .419** -.388** .312* .411** .428** 0.113 0.267 .316* -0.202 -0.338 .418* -.365** -0.123 .356* 0.28 .567** .444** .497** 
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4. Discussion. 269 
 270 
The MBT was developed with the express aim of supplying clinicians and researchers with a 271 
functional upper limb assessment that is sensitive to people with all stages with HD and 272 
therefore reflects the progressive basal ganglia degeneration in this disease. Performance in 273 
the MBT could distinguish between people gene positive with HD and healthy controls, as 274 
well as people with different stages of HD. Participants with manifest HD performed 275 
significantly more slowly and less accurately with increasing item complexity, resulting in a 276 
lower MBT total score compared to that seen in pre-manifest and control groups. MBT 277 
performance also significantly correlated with the UHDRS, quality of life and functional 278 
questionnaire measures. 279 
 280 
The mean MBT total scores revealed that the MBT was sensitive to all stages of disease, but 281 
not between controls and pre-manifest HD participants. This could have been due to the 282 
relatively small pre-manifest sample (n=8). Overall, the time taken to perform the MBT and 283 
the MBT total score deteriorated in a stepwise manner between groups as HD progressed. 284 
Control and pre-manifest participants performed the MBT most quickly and achieved the 285 
greatest total scores, whereas stage 4 and 5 participants were slowest in their performance of 286 
the MBT. We believe that the successful performance of the MBT requires intact basal 287 
ganglia function given the complex motor planning, motor initiation and motor accuracy 288 
required in the test [25,36]. Thus, as the cortico-basal ganglia-thalamo circuitry progressively 289 
degenerates in people with HD [37], this could lead to slower and less accurate MBT 290 
performance, resulting in lower MBT total scores.   291 
 292 
One reason for slower performance in more advanced disease stages could be increased 293 
difficulty automating tasks. In a previous study, healthy controls and people with pre-294 
manifest HD gradually improved in a motor skill task when repeatedly performed, whereas 295 
people with manifest HD did not [38]. Participants were required to use their finger to direct 296 
a cursor to a target that was reflected onto a mirror. The results from the study revealed that 297 
people with manifest HD were slower, less accurate and produced more variable trajectories 298 
over repeated sessions, whereas controls and pre-manifest participants improved, gradually 299 
becoming quicker whilst remaining accurate over sessions. One reason for this could be that 300 
controls and pre-manifest HD participants have the ability to automate movement, which in 301 
turn would free attentional resources that could be directed to the secondary task [29]. Given 302 
that the basal ganglia is implicated in automatic, habitual tasks, it could be involved in 303 
automating aspects of dual task performance [24,39,40]. Therefore, it may be that with 304 
increasing basal ganglia circuit degeneration the difficulties in multi-tasking experienced by 305 
people with HD are two-fold; Not only do they have limited attentional capacity, but they 306 
may also have difficulty carrying out simple, automatic tasks. 307 
 308 
Importantly, participant performance in pre-manifest and stage 1 groups significantly differ 309 
for the Complex Transfer and Dual Transfer tasks; these disease stages being the most 310 
commonly targeted for clinical trials to test the effectiveness of new treatments [41,42]. To 311 
our knowledge, there is no other functional upper limb assessment available that is able to 312 
distinguish the subtle performance differences between pre-manifest HD and stage 1. This 313 
difference was only evident in the more complex MBT items (Complex Transfer and Dual 314 
Transfer tasks) and not in the Baseline Transfer, which supports our approach of 315 
incorporating different levels of complexity when assessing functional ability in HD. An 316 
initial hypothesis was that participant performance would deteriorate with increased item 317 
complexity. Although participants in stages 1, 2, 3 and 4,5 performed significantly more 318 
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slowly in the Complex Transfer and Dual Transfer tasks relative to baseline, there was no 319 
significant performance difference between the Complex Transfer and Dual Transfer task in 320 
stages 1, 2 or 3.  One explanation for this could be practice effects due to the familiarity of 321 
the values presented on the tokens. To overcome this, a new version of the MBT has been 322 
developed entitled the Clinch token transfer test (C3t; See Figure 4). This consists of tokens 323 
with different values for the Complex Transfer and Dual Transfer task. As healthy controls 324 
and pre-manifest participants maintained performance across the MBT Baseline Transfer, 325 
Complex Transfer and Dual Transfer task, the aim of the Clinch token transfer test is to 326 
reduce the chances of practice effects and to test whether performance differs with increased 327 
complexity between healthy controls and people with pre-manifest HD. 328 
 329 
Uniquely in this study, we have considered relationships between performance on the MBT 330 
and relevant clinical domains. Performance scores (time taken and MBT total) in the MBT 331 
Transfer items significantly correlated with all UHDRS measures, evidencing strong 332 
convergent validity. This was also true for the SF-12 physical summary, the function 333 
component of the Late-Life Functional Disability Instrument, the Timed up and Go and the 334 
Sit to stand, which are all measures used to assess performance in daily functional tasks. 335 
MBT transfer tasks were also correlated with CAG disease burden score, which again 336 
suggests that MBT performance is capable of tracking disease stage in HD. The CAG disease 337 
burden score is particularly useful for pre-manifest patients as they are typically 338 
heterogeneous, with some people closer to disease onset than others [43]. As the pre-manifest 339 
group in this study was relatively small (n=8), an aim for future research involves recruiting a 340 
larger group of pre-manifest patients to identify if the MBT is capable of identifying people 341 
far from and close to manifest disease onset. Interestingly the MBT Dual Transfer total also 342 
correlated with the apathy score from the Problem behaviour assessment, revealing that the 343 
more apathetic the subject, the worse the total score in the MBT Dual Transfer task. This 344 
suggests that more complex tasks could be helpful identifying apathetic from non-apathetic 345 
subjects. However, we suggest other apathy assessments such as the Apathy Evaluation scale 346 
[44] would also need to be used to provide a reliable conclusion to these findings. The MBT 347 
did not correlate with the executive function summary from the Problem behaviour 348 
assessment. However, as the MBT items significantly correlated with the Symbol digit test, 349 
the Stroop tasks and the Letter verbal fluency, which are measures of executive function [45], 350 
this suggests that the ordinal scale used to rate the Problem behaviour assessment may not be 351 
as accurate measuring executive function as performance based measures.  352 
Additionally, results also revealed that all MBT items significantly correlated with the upper 353 
limb score of the Late-Life Functional Disability Instrument, suggesting that MBT 354 
performance relates to daily tasks that require upper limb function. Furthermore, all MBT 355 
scores also correlated with the lower limb score of the Late-Life Functional Disability 356 
Instrument. This suggests the MBT could be used as a general measure of function in HD.  357 
 358 
The MBT is a novel dual-task assessment that has potential to provide sensitive feedback to 359 
clinicians and researchers regarding upper limb function in people with HD. The objective 360 
scoring methods that are used in the MBT, as opposed to ordinal rating scales, are crucial for 361 
interventions where symptom changes are gradual and can be subtle, such as cell 362 
transplantation [46]. As an assessment, the MBT is quick to perform, inexpensive to produce 363 
and easily stored, which avoids the common problem of restricted space in clinical settings. 364 
Furthermore, the fact that it requires minimal researcher training and is independent of both 365 
language and culture barriers makes it an attractive outcome measure for clinical trials 366 
globally. The test can also be supplemented with accelerometers for the in-depth assessment 367 
of motion parameters. These have been used in previous studies to measure gait parameters in 368 
15 
people with pre-manifest and manifest HD, and to quantify tremor severity in people with 369 
Parkinson’s disease [47,48]. We have applied them in HD during the performance of the 370 
MBT, and were able to identify movement features that were able to distinguish between 371 
manifest and pre-manifest HD groups [49]. Subsequent to the development of the initial 372 
MBT, the test has undergone some minor amendments to develop an advanced prototype for 373 
full evaluation in a clinical setting. It has been renamed as Clinch Token Transfer Test (C3t).  374 
 375 
<INSERT FIGURE 4 HERE> 376 
 377 
A limitation of the MBT is the increased exposure to the token values across the value 378 
baseline, Complex Transfer and Dual Task. To minimise the chances of practice effects, the 379 
C3t test procedure was designed so different token values are presented for the Transfer 380 
Complex and the Dual task. Furthermore, as a caveat of this study is the lack of longitudinal 381 
data, future work will focus on evaluating performance over time of the new version of the 382 
MBT (namely, the C3t), as well as extending the application to other conditions with basal 383 
ganglia dysfunction, such as Parkinson’s disease and subtypes of epilepsy. 384 
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List of Table Legends 559 
Table 1: Criteria used to develop the MBT  560 
Table 2: Mean MBT participant demographic and clinical information revealed manifest 561 
subjects were significantly older than pre-manifest subjects, and stage 2 subjects were 562 
significantly older than healthy controls. There was no significant difference between any 563 
other group for any other variable. 564 
Table 3: Mean, standard deviation and 95% confidence intervals for time taken and mean 565 
MBT total scores achieved for each group (Control, Pre-manifest, Manifest; HD disease 566 
stage) during each of the MBT transfer items (MBT Baseline Transfer, Complex Transfer and 567 
Dual Transfer). 568 
Table 4: MBT convergent validity revealed that MBT performance (time and MBT total 569 
score) in the transfer tasks significantly correlated with all UHDRS motor, function and 570 
cognitive assessments. Performance in all transfer tasks significantly correlated with the SF-571 
12 physical summary and functional assessments including the Timed Up and Go, Sit to 572 
Stand and the Late Life Functional Disability Instrument domains. There was also a 573 
significant correlation between the Dual Transfer and Problem Behaviour Assessment Apathy 574 
score. 575 
 576 
List of Figure Legends 577 
Figure 1: The Moneybox test is enclosed in a case when not in use and when opened the 578 
contents required for testing are revealed. 579 
Figure 2: The Moneybox test (MBT) procedure and rating method. The subject is required to 580 
pick up the tokens with their non-dominant hand (A), transfer to their dominant hand (B) and 581 
release it into a moneybox (C). The time (in seconds) taken to perform the transfer tasks, the 582 
accuracy (referring to any errors or dropped tokens made during the task) are recorded and 583 
used to calculate the MBT total score. The alphabet rate is the number of correct letters of the 584 
alphabet recited per second and used to compare alphabet baseline performance to alphabet 585 
performance during the Dual Transfer task. 586 
Figure 3: The mean time taken is plotted in (A) and the mean MBT total scores are plotted in 587 
(B). Healthy controls and people in the early disease stages (stage 1) performed the transfer 588 
tasks significantly faster than those in the later disease stages (stage 4,5). The same stepwise 589 
performance deterioration is evident according to the MBT total scores, from which healthy 590 
controls and people in the early disease stages achieved a greater MBT total score (indicative 591 
of a faster time and greater accuracy) compared to those in the more advanced disease stages. 592 
Significant differences between participant groups are presented in the tables, where * 593 
p<0.05, ** p<0.01, *** p<0.001. 594 
Figure 4: The Clinch Token Transfer Test (C3t) is an optimised version of the Moneybox 595 
test (MBT). In preparation for dissemination and use in clinical trials, the C3t was developed 596 
so test components are made of robust materials that can be cleaned. It is also compact, with 597 
all test components contained within the case. The test procedure is more efficient, with token 598 
trays prepared and stacked ready for use so there is no set up time for the researcher between 599 
assessment items. Although the C3t procedure is ultimately the same as the MBT, unlike the 600 
MBT, the Dual Transfer task consists of tokens with different values to those in the Complex 601 
Transfer, which was added to reduce potential practice effects. Therefore, in the C3t, an 602 
additional value baseline item was added (Complex Value baseline), which proceeds the 603 
original Simple Value baseline.  604 
